MiKaela Olsen, DNP, APRN-CNS, AOCNS®, FAAN
Clinical Program Director, Oncology – The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center
MiKaela M. Olsen, DNP, APRN-CNS, AOCNS®, FAAN, is the Clinical Program Director for Oncology at the Johns Hopkins Hospital and the Johns Hopkins Health System. Dr. Olsen serves as adjunct faculty for the Johns Hopkins School of Nursing and Faculty Associate at the University Of Maryland School Of Nursing.
Dr. Olsen received her Bachelor of Science in Nursing from Texas Christian University in Fort Worth Texas in 1989 and a Master of Science degree with special emphasis in Oncology nursing from the University of California at San Francisco in 1996. She graduated with her Doctor of Nursing Practice degree from University of Maryland in 2019. She is a certified Advanced Oncology Clinical Nurse Specialist.
Dr. Olsen is the manager of the peripherally inserted central line catheter (PICC) team for the department of oncology, the chair of the Johns Hopkins Hospital Venous Access Device Committee, and chair of the CLABSI reduction subcommittee. Dr. Olsen is co-editor of the ONS Safe Handling of Hazardous Drugs Guidelines (2018) and co-editor for the ONS Chemotherapy and Biotherapy Guidelines and Recommendations for Practice (2014), which sold over 97,000 copies. She is currently the lead editor for the 1st edition of the Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (2019). She served on the American Society of Clinical Oncology (ASCO) and ONS Chemotherapy Safety Standards Workgroup (2016). She is the lead editor of the book “Hematologic Malignancies in Adults”, the first nursing textbook published to guide nurses in the care of hematologic malignancy patients. Dr. Olsen has published and extensively presented on the topic of VAD evidence-based practice and CLABSI reduction and safe handling of hazardous drugs.
Working closely with the Institute for Safe Medication Practices (ISMP) as an expert advisory panelist, she has written recommendations for safe administration of chemotherapy and adult intravenous push medications. To increase nurses knowledge of the potential serious health risks associated with HD exposure, she assisted in the development of ONS continuing education (CE) courses. As an instructor and consultant, Dr. Olsen has traveled to countries including Singapore, UAE, China, Bulgaria, and Japan to increase awareness of HD exposure risks and safe handling and prevention of CLABSIs.
